Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Current Assets data on file, last reported at $4.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 29.1% year-over-year to $4.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (up 29.1% YoY), and the FY2025 full-year result was $4.1 billion, up 22.92% from the prior year.
• Current Assets for Q1 2026 stood at $4.2 billion, up from $4.1 billion in the prior quarter.
• Across five years, Current Assets topped out at $4.2 billion in Q1 2026 and bottomed at $2.5 billion in Q2 2022.
• The 5-year median for Current Assets is $3.0 billion (2024), against an average of $3.1 billion.
• The widest annual swing landed in 2022, when Current Assets decreased 9.3%; it then rose 29.1% in 2026.
• A 5-year view of Current Assets shows it stood at $2.7 billion in 2022, then grew by 10.79% to $3.0 billion in 2023, then gained by 10.48% to $3.3 billion in 2024, then climbed by 22.92% to $4.1 billion in 2025, then grew by 4.16% to $4.2 billion in 2026.
• The last three Current Assets figures came in at $4.2 billion (Q1 2026), $4.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.

Peer Comparison